Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin

Fractionated radioimmunotherapy with90Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer

(2012) Allyson J. Ocean et al.   CANCER

PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma

(2012) David V. Gold et al.   CANCER

Mucin-based Targeted Pancreatic Cancer Therapy

(2012) Maria P. Torres et al.   CURRENT PHARMACEUTICAL DESIGN

Treatment of Advanced Pancreatic Carcinoma with 90Y-Clivatuzumab Tetraxetan: A Phase I Single-Dose Escalation Trial

(2011) S. A. Gulec et al.   CLINICAL CANCER RESEARCH

Glycosylation Variants of Mucins and CEACAMs As Candidate Biomarkers for the Diagnosis of Pancreatic Cystic Neoplasms

(2010) Brian B. Haab et al.   ANNALS OF SURGERY

Detection of Early-Stage Pancreatic Adenocarcinoma

(2010) D. V. Gold et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Current status of mucins in the diagnosis and therapy of cancer

(2009) Satyanarayana Rachagani et al.   BIOFACTORS

The Prevalence and Nature of Glycan Alterations on Specific Proteins in Pancreatic Cancer Patients Revealed Using Antibody-Lectin Sandwich Arrays

(2009) Tingting Yue et al.   MOLECULAR & CELLULAR PROTEOMICS